[Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
A 69 year-old male with carcinoid syndrome and undetectable primary tumour, but disseminated liver metastases, was treated with somatostatin analogue octreotide (Sandostatin) and later additionally with recombinant interferon alpha 2 b (r IFN alpha 2 b, Intron A). The carcinoid symptoms (flushing, diarrhoea) were stopped within hours by octreotide. Simultaneously, the urinary 5-hydroxyindolacetic acid (5-HIAA) excretion and serum serotonin levels decreased by more than 50%. In spite of continued treatment with r IFN alpha 2 b a reduction in dosage of octreotide resulted in a rapid recurrence of carcinoid symptoms, suggesting that IFN alpha 2 b had no effect on the carcinoid symptoms in this patient. Since, furthermore, no regression of the tumour mass was observed, treatment with IFN was stopped after 8 months. During 15 months of treatment to date the patient has been kept free of symptoms by octreotide.
Linkesch
M
M
II. Medizinische Universitätsklinik, Wien.
Kuzmits
R
R
Geyer
G
G
D000368:Aged; D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000628:therapy*; D009382:Neoplasms, Unknown Primary / Q000628:therapy*; D015282:Octreotide / Q000627:therapeutic use*; D011994:Recombinant Proteins
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015282:Octreotide
Therapie des metastasierten Karzinoids mit dem Somatostatin-Analogon Octreotid und mit rekombinantem Interferon alpha 2 b.